Currently out of the existing stock ratings of Mark Breidenbach, 157 are a BUY (98.74%), 2 are a HOLD (1.26%).

Mark Breidenbach

Work Performance Price Targets & Ratings Chart

Analyst Mark Breidenbach, carries an average stock price target met ratio of 39.55% that have a potential upside of 46.54% achieved within 205 days. Previously, Mark Breidenbach worked at OPPENHEIMER, ROTH MKM, HC WAINWRIGHT.

Mark Breidenbach’s has documented 292 price targets and ratings displayed on 30 stocks. The coverage was on Healthcare, Industrials, Technology, Consumer Cyclical sectors.

Most recent stock forecast was given on EPIX, ESSA Pharma at 13-Dec-2023.

Wall Street Analyst Mark Breidenbach

Analyst best performing recommendations are on KDMN (KADMON HOLDINGS).
The best stock recommendation documented was for ARVN (ARVINAS) at 12/14/2020. The price target of $80 was fulfilled within 8 days with a profit of $21.62 (37.03%) receiving and performance score of 46.29.

Average potential price target upside

of $111.47 (87.19%) on MCRB (SERES THERAPEUTICS).
of $86 (175.51%) on BL (BLACKLINE).
of $33.5 (74.15%) on KDNY (CHINOOK THERAPEUTICS).

ALLO Allogene Therapeutics ARVN Arvinas BLUE Bluebird bio CRBU Caribou Biosciences EPIX ESSA Pharma GBT Global Blood Therapeutics GMDA Gamida Cell Ltd IOVA Iovance Biotherapeutics MBIO Mustang Bio MCRB Seres Therapeutics SYBX Synlogic CGEN Compugen FMTX Forma Therapeutics Holdings IMRX Immuneering Corp ALPN Alpine Immune Sciences KDMN Kadmon Holdings SYRS Syros Pharmaceuticals ACHL Achilles Therapeutics PLC ADR CUE Cue Biopharma FTSV Forty Seven NRIX Nurix Therapeutics BLRX BioLineRx Ltd ADRO Aduro Biotech KDNY Chinook Therapeutics AL Air Lease BL Blackline FTS Fortis GBTG Global Business Travel Group GM General Motors Company MESO Mesoblast Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Robert Burns (HC WAINWRIGHT)